Medical congresses bring together healthcare professionals to share information about their specialties. MEDICALLY compiles and shares Roche and Genentech's congress materials from medical congresses around the world. Meaning publications related to Roche medicines presented at the main International Scientific Congresses will be made available on this page at the end of the embargo and for a limited period of time.
The information contained in the materials may include data on experimental drugs and medical devices which are subject to active clinical research , pending approval by any regulatory authority or reimbursement by the RIZIV/INAMI.
This information does not in any way constitute a tool to promote the prescription, supply, sale or consumption of medicines outside of what is stated in the authorized SmPC. It is therefore recommended to use the drug strictly following what is outlined in the SmPC to which reference is made for any further information. For further information on these materials or other medical insights regarding Roche drugs, you can refer to the Medical Department of Roche Belux through the Medical Information number +32 (0)2 525 82 99, the email@example.com mailbox or the https://medinfo.roche.com/ portal.
To consult the Summary of Product Characteristics of the individual medicines authorized in Belgium, please refer to the e-compendium website, Roche.be or RochePro websites.
Drug Safety: Concerning Risdiplam (Evrysdi), Phesgo, Xofluza, Polivy, Ocrevus, Hemlibra, Roaccutane, Rozlytrek, Enspryng (Satralizumab), Ronapreve (Casirivimab + Imdevimab), GAVRETO (Pralsetinib), Lunsumio (mosunetuzumab)
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the Summary of Product Characteristics (SmPC) for information on how to report adverse reactions.
If a pregnancy occurs while using Herceptin/PERJETA/Kadcyla/Phesgo or within 7 months following the last dose of Herceptin/Kadcyla/Phesgo or within 6 months following the last dose of PERJETA, please immediately report pregnancy to the local Roche Adverse Event line at +32 (0)2 525 82 99.Additional information will be requested during a Herceptin/PERJETA//Phesgo/Kadcyla-exposed pregnancy and the first year of the infant's life. This will enable Roche to better understand the safety of Herceptin/PERJETA/Kadcyla/Phesgo and to provide appropriate information to health authorities, healthcare providers and patients.
The reporting of suspected adverse reactions occurring after the authorization of the medicine is very important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to Roche Belux as the local MA holder of the drug via the email address firstname.lastname@example.org or via the Roche Belux Adverse Event line at +32 (0)2 525 82 99.
The available publications are documents protected by copyright, i.e. Roche is authorized to distribute a copy of the articles for personal use only, for study or research purposes, and may not be disclosed to third parties. Anyone who reproduces or distributes copies of such publications may be held liable for copyright infringement.
Preview the latest congresses
Browse information about latest congresses and view the congress calendar
Preview the latest medical materials
Take a look at materials from the latest medical congresses